Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy
Chimeric antigen receptor–engineered (CAR) T cells are emerging powerful therapies for patients with refractory/relapsed B-cell lymphomas. [<sup>18</sup>F]FDG PET/CT plays a key role during staging and response assessment in patients with lymphoma; however, the evidence about its utility...
Main Authors: | Flavia Linguanti, Elisabetta Maria Abenavoli, Valentina Berti, Egesta Lopci |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/19/4700 |
Similar Items
-
Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma
by: Vijay Mistry, et al.
Published: (2023-01-01) -
Gallbladder Involvement of Diffuse Large B-Cell Lymphoma with 18F-FDG PET/CT
by: Esra Arslan, et al.
Published: (2022-05-01) -
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
by: Panagiotis Samaras, et al.
Published: (2013-05-01) -
Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach
by: Alberto Miceli, et al.
Published: (2021-09-01) -
Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
by: Cristina Ferrari, et al.
Published: (2021-03-01)